Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Results from Allergic Conjunctivitis Phase 2b Clinical Trial

Wednesday, June 14, 2017 Clinical Trials News
Email Print This Page Comment bookmark
Font : A-A+

LEXINGTON, Mass., June 13, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage

biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to aldehyde toxicity, announced they will host a conference call and webcast on Wednesday, June 14, 2017 at
8:00 A.M. EDT to discuss results from its Phase 2b Allergic Conjunctivitis Trial.

The dial-in numbers are 1-877-870-4263 for domestic callers and 1-412-317-0790 for international callers.  A live webcast of the conference call will also be available on the investor relations page of the Aldeyra Therapeutics corporate website at www.aldeyra.com

After the live webcast, the event will remain archived on the Aldeyra Therapeutics website for one year.

About Aldeyra TherapeuticsAldeyra Therapeutics, Inc. is a biotechnology company devoted to improving lives by inventing, developing and commercializing products that treat diseases thought to be related to endogenous aldehydes, a naturally occurring class of pro-inflammatory and toxic molecules. Aldeyra's lead product candidate, ADX-102, is an aldehyde trap in development for ocular inflammation, as well as for Sjögren-Larsson Syndrome and Succinic Semi-Aldehyde Dehydrogenase Deficiency, two inborn errors of aldehyde metabolism. Aldeyra's product candidates have not been approved for sale in the U.S. or elsewhere.

Corporate Contact:Stephen TulipanoAldeyra Therapeutics, Inc.Tel: +1 781-761-4904 ext. 205 [email protected]

Investor Contact:Chris BrinzeyWestwicke PartnersTel: 339-970-2843[email protected]

Media Contact:Cammy Duong MacDougall Biomedical Communications 781-591-3443[email protected]

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/aldeyra-therapeutics-schedules-conference-call-and-webcast-to-announce-results-from-allergic-conjunctivitis-phase-2b-clinical-trial-300473316.html

SOURCE Aldeyra Therapeutics, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook